Company Overview
Snapshot
Founded in October 1996, OrSense operates with 11–50 employees. The company has raised a total of $44.4 million across 6 funding rounds from 3 investors. In May 2019, OrSense received FDA market clearance for its NBM200 noninvasive hemoglobin system, marking a significant regulatory achievement.
Business overview
OrSense is a medical device company specializing in the development and commercialization of noninvasive monitoring technologies. The company's core product, based on its patented SpectOLight technology and occlusion spectroscopy, utilizes a finger-attached, ring-shaped sensor probe to measure blood parameters such as hemoglobin, oxygen saturation, and glucose. This technology generates a strong optical signal by temporarily occluding blood flow, enabling sensitive and specific blood analysis. OrSense serves the health tech and life sciences sectors, providing solutions for continuous and spot measurements in medical applications.
Strategic signal
In May 2019, OrSense secured FDA market clearance for its NBM200 noninvasive hemoglobin system, making it the first noninvasive hemoglobin system approved for use in blood donation centers. This regulatory approval is a strong validation of OrSense's technology and opens up significant market opportunities within the blood donation and transfusion industry, signaling potential for broader adoption of its noninvasive monitoring solutions.
Log in to access full profile ›Company Intelligence Q&A
- What significant regulatory milestone did OrSense achieve?
- In May 2019, OrSense received FDA market clearance for its NBM200, making it the first noninvasive hemoglobin system cleared for use in blood donation centers. This approval validates the company's technology for a critical medical application.
- When did OrSense deliver its first systems in Mexico?
- In October 2014, OrSense delivered its first systems in Mexico, expanding its market presence internationally.
- Which investors participated in OrSense's May 2011 funding round?
- In May 2011, OrSense received funding from investors including Lewis Trust Group.
- What was a key funding event for OrSense in 2006?
- In February 2006, OrSense completed a private financing round, with participation from Lewis Trust Group.
- What was a notable early funding event for OrSense?
- In August 2001, OrSense raised capital from VC funds, including Israel HealthCare Ventures and Star Ventures, to support its development of noninvasive blood parameter monitoring technologies.